Michael Ibach, MD
Gastroenterology · Jacksonville Beach, FLNPI 1053362723
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,264 of the $3,625 with a category attached, or 62.5%. 22 manufacturers reported payments, led by Adare Pharmaceuticals, Inc. at 40.3% of the total. Reporting peaked in 2020 at $1,543 and has fallen 80.6% since, to $299 in 2025. That places this record below the midpoint for gastroenterology clinicians in FL, where the typical reported total is $3,025.
Across 91 payments — averaging $39.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Adare Pharmaceuticals, Inc.$1K
- AbbVie$359
- Johnson & Johnson$357
- Enterra Medical, Inc.$207
- Sanofi$197
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$179
- plus $866 from 16 others
Across 16 payments — averaging $60,559 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$556K
- AstraZeneca$355K
- Adare Pharmaceuticals, Inc.$44K
- E.r. Squibb & Sons, L.L.C.$14K
What the payments were for
- Consulting fees$180%
- Travel & lodging$1,24334%
- Food & beverage$2,26462%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Adare Pharmaceuticals, Inc. | 5 | $1,459 |
| AbbVie(2 entities) | 19 | $359 |
| Johnson & Johnson | 16 | $357 |
| Enterra Medical, Inc. | 1 | $207 |
| Sanofi | 6 | $197 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $179 |
| AstraZeneca | 3 | $159 |
| Regeneron Healthcare Solutions, Inc. | 2 | $133 |
| Merck | 4 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Pfizer | 3 | $62 |
| Bristol Myers Squibb | 3 | $52 |
| Olympus America Inc. | 1 | $50 |
| Medtronic | 1 | $47 |
| Intercept Pharmaceuticals, Inc. | 3 | $45 |
| Braintree Laboratories, Inc. | 3 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Ambu Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Ardelyx, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$114
How this compares
$3,625 in reported general payments places this provider in the 50th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 17 | $37,621 |
| LinzessLinaclotide | 14 | $10,286 |
| Mesalamine | 16 | $6,935 |
| Budesonide DrBudesonide | 15 | $3,296 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 170 | $2,359 |
| Ursodiol | 11 | $1,837 |
| Balsalazide Disodium | 13 | $1,724 |
| Dicyclomine Hcl | 65 | $1,085 |
| Famotidine | 78 | $1,051 |
| Pantoprazole Sodium | 119 | $967 |
| Sucralfate | 51 | $954 |
| Omeprazole | 77 | $823 |
| Esomeprazole Magnesium | 13 | $530 |
| Ondansetron OdtOndansetron | 28 | $512 |
| Octreotide Acetate | 17 | $441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $23 | $37,62117 claims |
| AbbVieLinzess | $359 | $10,28614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Jacksonville Beach
- Nikhil KapilaJacksonville Beach$63K
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
- Ronen AraiCoral Springs$1.1M
- Charles SninskyGainesville$983K
- Peter DraganovGainesville$832K
- Arin NewmanMiami Beach$716K
- Joanna LopezMiami$670K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.